Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+

Update Il y a 4 ans
Reference: NCT01354457

Woman and Man

  • | Country :
  • France
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The purpose of this study is to determine whether fractionated RIT with Epratuzumab and radiolabeled Epratuzumab are effective in the treatment of relapsing or refractory ALL.


Inclusion criteria

  • Acute Lymphoblastic Leukemia

Links